Gsa Capital Partners LLP Chroma Dex Corp. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.48 - $2.19 $35,333 - $52,284	23,874 Added 29.89%	103,742 $158,000
Q4 2022 Feb 13, 2023	BUY	$1.25 - $1.94 $99,835 - $154,943	79,868 New	79,868 $134,000
Q2 2022 Aug 09, 2022	SELL	$1.59 - $2.7 $55,829 - $94,805	-35,113 Reduced 64.68%	19,176 $32,000
Q1 2022 May 11, 2022	BUY	$2.02 - $3.92 $109,663 - $212,812	54,289 New	54,289 $134,000
Q2 2021 Aug 05, 2021	SELL	$6.66 - $10.92 $132,440 - $217,155	-19,886 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$4.59 - $18.74 $180,547 - $737,137	-39,335 Reduced 66.42%	19,886 $186,000
Q4 2020 Feb 03, 2021	SELL	$3.93 - $5.5 $13,939 - $19,508	-3,547 Reduced 5.65%	59,221 $284,000
Q3 2020 Nov 06, 2020	BUY	$4.01 - $5.56 $251,699 - $348,990	62,768 New	62,768 $252,000
Q4 2018 Feb 12, 2019	SELL	$2.8 - $4.22 $38,360 - $57,814	-13,700 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$3.5 - $4.91 $133,700 - $187,562	-38,200 Reduced 73.6%	13,700 $59,000
Q2 2018 Aug 09, 2018	BUY	$3.22 - $4.43 $167,118 - $229,916	51,900 New	51,900 $193,000

17.2M

66.7K

8.2K

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $360M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.